DDInter1607 DDInter1137
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Medroxyprogesterone acetate
Ritonavir {u} (Compound) causes {v} (Side Effect) Palpitations
Palpitations {u} (Side Effect) is caused by {v} (Compound) Medroxyprogesterone acetate
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Medroxyprogesterone acetate
Ritonavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Testosterone
Testosterone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Ritonavir {u} (Compound) causes {v} (Side Effect) Palpitations
Palpitations {u} (Side Effect) is caused by {v} (Compound) Testosterone
Testosterone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Ritonavir {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Ritonavir {u} (Compound) causes {v} (Side Effect) Malignant melanoma
Malignant melanoma {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Medroxyprogesterone acetate
Ritonavir {u} (Compound) causes {v} (Side Effect) Paralysis
Paralysis {u} (Side Effect) is caused by {v} (Compound) Delavirdine
Delavirdine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Medroxyprogesterone acetate
Ritonavir {u} (Compound) causes {v} (Side Effect) Cerebral ischaemia
Cerebral ischaemia {u} (Side Effect) is caused by {v} (Compound) Voriconazole
Voriconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Medroxyprogesterone acetate
Ritonavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Medroxyprogesterone acetate (Compound)
Ritonavir (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Medroxyprogesterone acetate (Compound)
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Ritonavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Hydrocortisone (Compound) and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Ritonavir (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Testosterone (Compound) and Testosterone (Compound) resembles Medroxyprogesterone acetate (Compound)
Ritonavir (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Testosterone (Compound) and Testosterone (Compound) resembles Medroxyprogesterone acetate (Compound)
Ritonavir (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Hydrocortisone (Compound) and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Ritonavir (Compound) causes Malignant melanoma (Side Effect) and Malignant melanoma (Side Effect) is caused by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate
Ritonavir (Compound) causes Paralysis (Side Effect) and Paralysis (Side Effect) is caused by Delavirdine (Compound) and Delavirdine may cause a minor interaction that can limit clinical effects when taken with Medroxyprogesterone acetate
Ritonavir (Compound) causes Cerebral ischaemia (Side Effect) and Cerebral ischaemia (Side Effect) is caused by Voriconazole (Compound) and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate